Observational studyScientific reports2026
Decreased serum MG53 levels are associated with SHBG and androgen excess in women with polycystic ovary syndrome.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07094776 (Evaluation of MG53), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by hormonal and metabolic abnormalities. Mitsugumin-53 (MG53), a multifunctional E3 ubiquitin ligase, is implicated in insulin signaling and oxidative stress regulation, yet its role in PCOS remains unclear. This study aimed to investigate serum MG53 levels in women with PCOS and explore their associations with hormonal, metabolic, and ovarian parameters. In this case-control study, 64 women with PCOS and 64 healthy controls with comparable age were enrolled. Serum MG53 concentrations were measured by ELISA. Associations between MG53 and continuous variables were assessed using Spearman's rank correlation. Independent determinants of MG53 were evaluated using multivariable linear regression (including age and BMI as covariates), and diagnostic performance for PCOS was assessed using receiver operating characteristic (ROC) analysis. Serum MG53 concentrations were lower in women with PCOS than in controls (median [IQR]: 124.4 [104.25-202.15] vs. 206.4 [131.63-316.58] pg/mL; p = 0.001). MG53 correlated positively with sex hormone-binding globulin (SHBG) (ρ = 0.274, p = 0.002) and inversely with ovarian follicle count (ρ = - 0.223, p = 0.011). In multivariable analysis, SHBG remained an independent positive determinant of MG53, whereas hirsutism and follicle count were independent negative predictors. MG53 demonstrated modest discrimination for PCOS (AUC = 0.667, 95% CI 0.569-0.762), with 57.8% sensitivity and 75.0% specificity at an exploratory cut-off of 131.1 pg/mL. Serum MG53 is reduced in PCOS and is associated with SHBG and features related to androgen excess and ovarian morphology. These cross-sectional findings support MG53 as a candidate biomarker reflecting metabolic-reproductive associations in PCOS; however, its diagnostic performance is modest and requires external validation.Trial registration Prospectively registered on ClinicalTrials.gov (NCT07094776) as an observational study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.